Presentation will cover new data on the long-term efficacy of
crofelemer (Mytesi®) based on a supplemental analysis of the ADVENT trial
SAN FRANCISCO--(BUSINESS WIRE)--Jun. 27, 2017--
Napo Pharmaceuticals, Inc., a human health company developing and
commercializing novel gastrointestinal prescription products from plants
used traditionally in rainforest areas, and Jaguar Animal Health, Inc.
(NASDAQ: JAGX) (Jaguar), announced today that new crofelemer (Mytesi®)
data from a supplemental analysis of the ADVENT trial will be featured
in a poster presentation at the 9th International Aids Society (IAS)
Conference on HIV Science. The meeting will be held from July 23 to 26,
2017 in Paris, France.
Presentation Title: Long-Term Crofelemer Use Gives Clinically
Relevant Reductions in HIV-Related Diarrhea
Presentation by Roger D. MacArthur, MD, Patrick Clay, PharmD, Gary
Blick, MD, Roger Waltzman, MD, Margie Bell, MS
Date and Time of Presentation: Wednesday, July 26, 2017, 12:30 – 4:30
p.m.
Dates and Time of Poster Display: Monday, July 24 - Wednesday, July 26,
12:30 – 4:30 p.m.
Location: Poster Exhibition area
Abstract Number: A-854-0101-01472
Launched by Napo Pharmaceuticals in October 2016, Mytesi® is the only
antidiarrheal studied in and U.S. FDA-approved for the symptomatic
relief of noninfectious diarrhea in adults living with HIV/AIDS on
antiretroviral therapy (ART). Mytesi® is a prescription treatment for
diarrhea that works differently, by acting locally in the GI tract to
normalize the flow of water. Mytesi® does not have drug-drug
interactions with ART and has side effects that are similar to placebo.
The IAS Conference on HIV Science features the latest HIV science,
including basic, clinical and prevention research. It brings together a
broad cross section of HIV professionals from around the world with a
focus on implementation – moving scientific advances into practice.
The poster for Napo’s presentation will be available on the IAS
website in July after the conference begins.
About Mytesi®
Mytesi® (crofelemer) is an antidiarrheal indicated for the
symptomatic relief of noninfectious diarrhea in adult patients with
HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not
indicated for the treatment of infectious diarrhea. Rule out infectious
etiologies of diarrhea before starting Mytesi®. If infectious
etiologies are not considered, there is a risk that patients with
infectious etiologies will not receive the appropriate therapy and their
disease may worsen. In clinical studies, the most common adverse
reactions occurring at a rate greater than placebo were upper
respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%),
flatulence (3.1%), and increased bilirubin (3.1%).
More information and complete Prescribing Information are available at Mytesi.com.
Crofelemer, the active ingredient in Mytesi®, is a botanical
(plant-based) drug extracted and purified from the red bark sap of the
medicinal Croton lechleri tree in the Amazon rainforest. Napo has
established a sustainable harvesting program for crofelemer to ensure a
high degree of quality and ecological integrity.
Proposed Merger
As announced March 31, 2017, Napo and Jaguar Animal Health, Inc. have
entered a definitive merger agreement. The proposed merger of Jaguar and
Napo remains subject to customary conditions to closing. Upon the
consummation of the merger, Jaguar’s name will be changed to Jaguar
Health, Inc., and Napo will operate as a wholly-owned subsidiary of
Jaguar, focused on human health. As previously stated, Jaguar and Napo
expect the merger to close by the end of July 2017.
About Napo Pharmaceuticals, Inc.
San Francisco-based Napo Pharmaceuticals, Inc., focuses on the
development and commercialization of proprietary pharmaceuticals from
rainforest resources for the global marketplace in collaboration with
local partners.
For more information, please visit www.napopharma.com.
About Jaguar Animal Health, Inc.
Jaguar Animal Health, Inc. is an animal health company focused on
developing and commercializing first-in-class gastrointestinal products
for companion and production animals, foals, and high value horses.
Canalevia™ is Jaguar’s lead prescription drug product candidate,
intended for the treatment of various forms of diarrhea in dogs.
Equilevia™ (formerly referred to as SB-300) is Jaguar’s prescription
drug product candidate for the treatment of gastrointestinal ulcers in
horses. Canalevia™ and Equilevia™ contain ingredients isolated and
purified from the Croton lechleri tree, which is sustainably
harvested. Neonorm™ Calf and Neonorm™ Foal are Jaguar’s lead
non-prescription products. Neonorm™ is a standardized botanical extract
derived from the Croton lechleri tree. Canalevia™ and Neonorm™
are distinct products that act at the same last step in a physiological
pathway generally present in mammals. Jaguar has nine active
investigational new animal drug applications, or INADs, filed with the
FDA and intends to develop species-specific formulations of Neonorm™ in
six additional target species, formulations of Equilevia™ in horses, and
Canalevia™ for cats and dogs.
For more information about Jaguar, please visit www.jaguaranimalhealth.com.
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking
statements.” These include statements regarding the proposed merger
between Jaguar and Napo, the expectation that the proposed merger will
close by the end of July 2017, Jaguar’s intention to develop
species-specific formulations of Neonorm™ in additional target species,
and Jaguar’s plan to develop formulations of Canalevia™ for cats, horses
and dogs. In some cases, you can identify forward-looking statements by
terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,”
“anticipate,” “could,” “intend,” “target,” “project,” “contemplate,”
“believe,” “estimate,” “predict,” “potential” or “continue” or the
negative of these terms or other similar expressions. The
forward-looking statements in this release are only predictions. Jaguar
has based these forward-looking statements largely on its current
expectations and projections about future events. These forward-looking
statements speak only as of the date of this release and are subject to
a number of risks, uncertainties and assumptions, some of which cannot
be predicted or quantified and some of which are beyond Jaguar’s
control. Except as required by applicable law, Jaguar does not plan to
publicly update or revise any forward-looking statements contained
herein, whether as a result of any new information, future events,
changed circumstances or otherwise.
Jaguar-JAGX
View source version on businesswire.com: http://www.businesswire.com/news/home/20170627005820/en/
Source: Jaguar Animal Health, Inc.
KCSA Strategic Communications
Kate Tumino, 212-896-1252
ktumino@kcsa.com
or
Lisa
Lipson, 508-843-6428
llipson@kcsa.com
